MOUNJARO® 12.5mg KwikPen®, 1 Stk.

Description

Name: MOUNJARO® 12.5 mg KwikPen®, 1 Stk.
Manufacturer: Eli Lilly and Company Limited
Active Substance(s): TIRZEPATIDE
Strength: 12.5mg/per 0.6 ml injection
Package Content: 1 box with 4 pre-filled KwikPens

MOUNJARO® 12.5mg KwikPen contains tirzepatide in a multidose injection pen designed for once-weekly administration. This higher maintenance strength is typically prescribed for adults who require additional glycemic control after progressing through lower doses. Each pen includes four prefilled weekly injections, supporting consistent treatment under the supervision of a qualified healthcare professional.

MOUNJARO® 12.5mg KwikPen contains tirzepatide — a dual GIP and GLP-1 receptor agonist developed by Eli Lilly and Company — delivered as a 12.5mg/0.6mL injection in a pre-filled pen with four once-weekly subcutaneous doses [5]. Indicated as an adjunct to diet and exercise for patients with type 2 diabetes mellitus, and for chronic weight management in eligible adults in jurisdictions where this indication is locally authorized, the 12.5mg strength is prescribed for patients who have tolerated the 10mg dose and require further escalation before any consideration of the maximum 15mg of tirzepatide [4]. Healthcare professionals looking to buy MOUNJARO® 12.5mg KwikPen online can contact the Maylips support team for product and ordering guidance.

Product Specifications

• Strength:5mg per 0.6mL
• Active Substance: Tirzepatide
• Dosage Form: Solution for injection, single-patient-use KwikPen with 4 doses
• S. Licensee: Eli Lilly and Company Limited
• Initial U.S. Approval: May 2022
• Molecular Type: Dual GIP/GLP-1 receptor agonist peptide
• Intended Use: Patients with type 2 diabetes mellitus; chronic weight management
• Package Dimensions: Width: 60mm • Height: 40mm • Length: 150mm • Weight: 60g

Regulatory status current as of mid-2026. Practitioners should verify applicable local regulatory requirements before prescribing or supplying.

MOUNJARO® 12.5mg KwikPen contains tirzepatide as its active substance — the International Nonproprietary Name (INN) for the dual GIP and GLP-1 receptor agonist present across all MOUNJARO® dose strengths. MOUNJARO® is Eli Lilly’s proprietary brand name; tirzepatide is the generic scientific designation for the molecule. Both terms identify the same pharmaceutical compound, with the same active substance, formulation, and mechanism of action regardless of dose strength or presentation [4].

In the United States, MOUNJARO® is approved specifically for improving glycemic control in adults with type 2 diabetes mellitus. Chronic weight management is not an approved indication under the MOUNJARO® brand name in the U.S.; that indication is authorized in the U.S. under a separate brand name for the same active substance. In international markets — including the UK and EU — the MOUNJARO® KwikPen may carry additional approved indications; practitioners should verify the applicable indication in their region before prescribing [4].

The 12.5mg strength is prescribed for patients who have tolerated the 10mg dose and require further therapeutic escalation before any clinical consideration of the maximum 15mg of tirzepatide. Each KwikPen is a single-patient-use pre-filled device delivering four doses of 12.5mg tirzepatide in 0.6mL per dose, administered once weekly by subcutaneous injection [5]. Dose escalation decisions at this stage should reflect individual tolerability, treatment response, and the patient’s current therapeutic goals rather than a fixed schedule [4].

Tirzepatide is a synthetic dual incretin mimetic that engages both GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptors via independent binding domains on a single peptide molecule [2]. This simultaneous dual-receptor activation structurally and pharmacologically distinguishes tirzepatide from single-pathway GLP-1 receptor agonists and drives the outcomes seen in the SURPASS clinical trials [1].

The dual pathways operate through distinct, complementary mechanisms:

• GLP-1 Receptor Agonism: Stimulates glucose-dependent insulin secretion, suppresses postprandial glucagon release, and delays gastric emptying. This reduces fasting and postprandial blood glucose while enhancing satiety, which supports glycemic control and weight reduction [2].
• GIP Receptor Agonism: Amplifies meal-stimulated insulin response, regulates adipose tissue lipid metabolism, and may lessen the severity of GI side effects typically associated with pure GLP-1 therapies [2]. This tolerability advantage is highly relevant at the 12.5mg dose, where near-maximum dual-receptor activity is achieved.

Data from the SURPASS program show that tirzepatide delivers robust reductions in HbA1c and body weight across diverse demographic subgroups [1]. Results from the SURPASS-2 trial further highlight the superior glycemic and weight-loss efficacy of higher-dose tirzepatide when compared directly against a standard GLP-1 receptor agonist [3]. Providers should consult the full prescribing information for complete pharmacological, titration, and interaction guidelines [4].

MOUNJARO® 12.5mg KwikPen is indicated across two clinical settings, each as an adjunct to diet and exercise. Approved indications vary by jurisdiction, and practitioners should confirm the applicable indication in their region against current local labeling before initiating therapy [4].

For patients with type 2 diabetes mellitus, MOUNJARO® is indicated to improve glycemic control in adults. It is not intended for type 1 diabetes or diabetic ketoacidosis [4]. The 12.5mg strength is appropriate for patients who have tolerated the 10mg dose and require further advancement toward glycemic targets; clinical evidence from the SURPASS program confirms the safety and efficacy of this titration step [1]. Escalation to 12.5mg should be based on the individual patient’s response and tolerability at 10mg, not applied as a universal next step [4].

For chronic weight management, eligibility in international markets where the MOUNJARO® KwikPen carries this indication generally covers adults with obesity (BMI ≥30 kg/m²) or those who are overweight (BMI ≥27 kg/m²) with at least one weight-related comorbidity, as adjunct therapy to a reduced-calorie diet and increased physical activity. As noted above, this indication is not authorized under the MOUNJARO® brand name in the U.S. [4]. Licensed practitioners looking to buy weight loss medicine for use in eligible patient programs should verify current local indications and prescribing requirements before initiating therapy.

Prior to escalating to 12.5mg, prescribers should assess renal and hepatic function, review concomitant basal insulin or sulfonylurea use, and confirm that the patient’s diet and exercise program remains active. Patient-specific factors including prior response, tolerability at 10mg, and overall therapeutic goals should inform the escalation decision [4].

MOUNJARO® 12.5mg KwikPen is administered once weekly by subcutaneous injection and may be given at any time of day, with or without food. Administering on the same day each week supports a consistent treatment schedule. Suitable injection sites include the abdomen, thigh, or upper arm, with rotation at each dose to minimize localized skin reactions [4].

Before each use, the solution should be inspected for clarity and the absence of visible particles or discoloration. A new needle must be attached for every injection, and the site prepared using aseptic technique. To administer, remove the cap, position the needle at the prepared site, press the injection button firmly, and hold the pen in place for approximately 10 seconds to confirm complete dose delivery. The dose window should be verified following injection, and used needles disposed of safely in an approved sharps container [5].

Patients using basal insulin alongside MOUNJARO® should administer each product at a separate injection site and be monitored for hypoglycemia, particularly during initiation and dose escalation. If a weekly dose is missed and fewer than four days have elapsed since the scheduled injection, it should be administered promptly and the regular schedule resumed. If more than four days have passed, the missed dose should be skipped entirely; doses must not be doubled within the same week [4]. Licensed practitioners looking to buy MOUNJARO® KwikPen wholesale can contact the Maylips support team for ordering guidance.

The safety profile of MOUNJARO® 12.5mg is characterized by the SURPASS clinical program and post-marketing data. Gastrointestinal (GI) adverse reactions are the most frequent, occurring primarily during dose escalation [1]. These effects—including nausea, vomiting, diarrhea, constipation, decreased appetite, and abdominal discomfort—are usually mild to moderate and typically improve over time with gradual titration [4]. Mild injection site reactions (redness, swelling, pruritus) may occur but resolve without intervention; weekly site rotation minimizes their frequency [4].

The risk of hypoglycemia is low when tirzepatide is used as monotherapy due to its glucose-dependent mechanism, but it increases when co-administered with basal insulin or sulfonylureas, requiring blood glucose monitoring and potential dosage adjustments of those concomitant therapies [4]. Serious but uncommon adverse reactions include acute pancreatitis, gallbladder disease, and renal impairment linked to dehydration from severe GI events [1]. No dose adjustment is required for mild-to-moderate renal or hepatic impairment [4].

MOUNJARO® is an FDA-approved prescription pharmaceutical, with initial U.S. approval on May 13, 2022, licensed by Eli Lilly and Company Limited [4]. Supply is restricted to licensed medical and healthcare professionals through authorized channels in accordance with applicable national regulations.

In the U.S., the MOUNJARO® brand is approved for improving glycemic control in adults with type 2 diabetes mellitus. Chronic weight management is not an approved indication under this brand name in the U.S. market. The MOUNJARO® KwikPen format may carry additional jurisdiction-specific approvals in international markets; practitioners must verify the applicable regulatory status in their region before prescribing, dispensing, or ordering this product [4].

When buying online, licensed practitioners should review applicable regulatory frameworks, product-specific clinical requirements, and relevant professional obligations to ensure that sourcing decisions align with local standards. Regulatory information is current as of June 2026; prescribers and dispensing professionals should confirm local requirements before use.

1. Permana H, Yanto TA, Hariyanto TI. Efficacy and safety of tirzepatide as novel treatment for type 2 diabetes: A systematic review and meta-analysis of randomized clinical trials. Diabetes Metab Syndr. https://pubmed.ncbi.nlm.nih.gov/36274410/
2. Coskun T, Sloop KW, Loghin C, et al. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept. Molecular Metabolism.https://pubmed.ncbi.nlm.nih.gov/30473097/
3. Frías JP, Davies MJ, Rosenstock J, et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. New England Journal of Medicine. https://www.nejm.org/doi/full/10.1056/NEJMoa2107519
4. S. Food and Drug Administration. MOUNJARO® (tirzepatide) injection prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215866s000lbl.pdf
5. Eli Lilly and Company. MOUNJARO® KwikPen strengths and doses. 2025. https://www.lilly.com/en-CA/resources/faq/mounjaro-kwikpen/strengths-and-doses

All content on this website is intended for informational purposes and does not constitute medical advice.

Warning! The product is intended solely for professional use in a medical environment and under professional supervision. The product is supplied to medical professionals who specialize in aesthetic medicine (plastic surgery, facial treatments) and work under individual medical licenses as aestheticians or in dedicated clinics. Unprofessional use by individuals without a medical background may lead to severe adverse effects and health harm.